NeuroXess Valuation, Funding & Investors

NeuroXess is valued at $47M as of January 2022.

Last NeuroXess valuation

$47M

Angel · Jan 2022

Last NeuroXess funding round

$105M

Series B · Oct 2026

Cumulative funding NeuroXess raised

$120M

across 2 funding rounds

Key investors in NeuroXess

  • IDG Capital
  • HSG
  • Shenzhen Capital Group
  • Yonghua Capital
  • Co-Stone Venture Capital
  • New Alliance Capital

NeuroXess Overview

About NeuroXess

NeuroXess is a China-headquartered provider of brain-computer interface hardware for neuroscience research. Its wireless neural acquisition systems feature 256-channel amplifiers and flexible cortical electrodes compatible with epilepsy monitoring and BCI decoding. NeuroXess supplies kits to Tsinghua University labs and offers MATLAB-based analysis software for stroke rehab protocols.


Founded

2021

HQ

ChinaGuangzhou

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$47M (Jan 2022)

NeuroXess Valuation

NeuroXess is currently valued at $47M, based on its angel round in January 2022.

The $15M round was led by HSG and Shanda Capital, with participation from New Alliance Capital and Yonghua Capital.

NeuroXess valuation by funding round

NeuroXess valuation by funding round
DateStageValuation
Jan 2022Angel$47M

NeuroXess Funding History

NeuroXess has raised a total of $120M across 2 funding rounds.

NeuroXess' first fundraising round was a $15M angel round in January 2022. The most recent completed round was a $105M Series B in October 2026.

NeuroXess funding rounds

NeuroXess funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Oct 2026Series BSDIC Unity Capital (lead); Shenzhen Capital Group (lead); TriWise Capital (lead); IDG Capital; ZWC Partners; China Fortune-Tech Capital; Zhongping Capital; Xichen Capital; Co-Stone Venture Capital; Huafu Securities Co., Ltd.; Shanda Group; Huangpu Biomedicine Industry Investment Fund Management$105M-NeuroXess raised RMB 700 million in a Series B round announced on 28 October 2026, co-led by SDIC Unity Capital, Shenzhen Capital Group and TriWise Capital. A long list of further investors took part, including China Fortune-Tech Capital, Co-Stone Venture Capital, Shanda Group, Xichen Capital, IDG Capital and Junxi Capital. The round coincided with the company's implantable brain-computer interface system entering a registration clinical trial. NeuroXess develops implantable flexible brain-computer interfaces and has built the whole chain from hardware to decoding algorithms in-house. Its system is aimed at patients with ALS, high-level paraplegia and stroke, to restore movement and speech. The company was founded in 2021 by chief scientist Dr Tao Hu and is headquartered in Shanghai, with a chip design base in Hengqin, a production site in the Ganjiang New Area in Jiangxi and a Hong Kong arm for overseas markets. It previously raised an angel and Pre-A round in 2022 and a Series A of several hundred million yuan in December 2022.
Jan 2022AngelHSG (lead); Shanda Capital (lead); New Alliance Capital; Yonghua Capital$15M$47MNeuroXess raised $13.9 million in a Series A round on December 28, 2022, from investors including HongShan (HSG), New Alliance Capital, Shanda Capital, Zhongping Capital, Boyi Equity Investment, GS Capital, Light Silver Capital, and Sailing Capital. NeuroXess has raised a total of $29.12 million across three rounds, including prior Seed VC and Angel rounds.

Who has invested in NeuroXess?

16 investors have backed NeuroXess across its funding rounds, including IDG Capital, HSG, Shenzhen Capital Group, Yonghua Capital, Co-Stone Venture Capital and New Alliance Capital.

Lead investors include SDIC Unity Capital, Shenzhen Capital Group, TriWise Capital, HSG and Shanda Capital.


NeuroXess Investors

Investors in NeuroXess by funding rounds participated
InvestorHQRoundsRoleFirst check
IDG CapitalHong KongHong Kong1ParticipantOct 2026
SDIC Unity CapitalChinaBeijing1LeadOct 2026
ZWC PartnersHong KongHong Kong1ParticipantOct 2026
China Fortune-Tech CapitalChinaShanghai1ParticipantOct 2026
New Alliance CapitalChinaShanghai1ParticipantJan 2022
Shanda CapitalChinaShanghai1LeadJan 2022
Zhongping CapitalChinaShanghai1ParticipantOct 2026
Xichen CapitalChinaChina1ParticipantOct 2026
Co-Stone Venture CapitalChinaShenzhen1ParticipantOct 2026
Shenzhen Capital GroupChinaShenzhen1LeadOct 2026
Huafu Securities Co., Ltd.ChinaFuzhou1ParticipantOct 2026
Shanda GroupUnited StatesSan Francisco, CA1ParticipantOct 2026
TriWise CapitalChinaShenzhen1LeadOct 2026

This data is available for Pro users. Sign up to see all 16 NeuroXess investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

NeuroXess Competitors

NeuroXess competitors include listed companies like Biohit and AnteoTech, and private ones like Lab n People, iSTAR Medical, Xcell Biosciences and Hilo.

Public and private companies comparable to NeuroXess
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Lab n PeopleSouth KoreaYangjuPrivate--$57M-
BiohitFinlandFinlandPublicly listed$18M$4M$37M1.9x
AnteoTechAustraliaAustraliaPublicly listed$324K($3M)$36M14.6x
iSTAR MedicalBelgiumLiègePrivate--$47M-
Xcell BiosciencesUnited StatesSan Francisco, CAPrivate--$47M-
HiloSwitzerlandNeuchâtelPrivate--$48M-

NeuroXess Public Comps

NeuroXess is still privately-owned, but its public comps include Sensus Healthcare, Svas Biosana, Myomo, Spectral AI, Singular Health, K Pharma, Daxor, Renalytix, Osang Healthcare and Ceretas.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Sensus Healthcare$27M($10M)1.2x1.6x(3.3x)(3.4x)
Svas Biosana$159M$21M0.7x0.7x5.1x5.1x
Myomo$41M($13M)1.3x1.2x(4.3x)(8.1x)
Spectral AI$20M($5M)2.6x2.7x(11.1x)-
Singular Health$990K($5M)42.1x20.8x(9.0x)(15.7x)
K Pharma-($6M)--(6.5x)-
Daxor$10M-4.8x5.5x--
Renalytix$3M($21M)18.0x18.0x(2.5x)-

This data is available for Pro users. Sign up to see all NeuroXess competitors and their valuation data.

Start Free Trial

Common questions about NeuroXess

When was NeuroXess founded?NeuroXess was founded in 2021.
Where is NeuroXess headquartered?NeuroXess is headquartered in Guangzhou, China.
Is NeuroXess publicly listed?No, NeuroXess is a private, VC-backed company.
What is NeuroXess' valuation?NeuroXess was last valued at $47M in its angel round in January 2022.
How much funding has NeuroXess raised?NeuroXess has raised $120M across 2 funding rounds.
What was NeuroXess' last funding round?NeuroXess' last funding round was a $105M Series B in October 2026, led by SDIC Unity Capital, Shenzhen Capital Group and TriWise Capital.
Who are NeuroXess' investors?NeuroXess' investors include IDG Capital, SDIC Unity Capital, ZWC Partners, China Fortune-Tech Capital, New Alliance Capital, Shanda Capital, Zhongping Capital, Xichen Capital, Co-Stone Venture Capital, Shenzhen Capital Group and 6 others.
Which companies are comparable to NeuroXess?Companies comparable to NeuroXess include Lab n People, Biohit, AnteoTech, iSTAR Medical, Xcell Biosciences and Hilo.

See companies similar to NeuroXess

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial